Government-Funded Scientists Laid the Groundwork for Billion-Dollar Vaccines
Drugmakers will walk away with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.
Drugs
581 - 600 of 1,300 Results
-
-
Patients Struggle to Find Prescription Opioids After NY Tax Drives Out Suppliers
The tax was touted as a way to generate funding for treatment programs across the state. But to avoid paying, scores of manufacturers and wholesalers stopped selling opioids in New York.
-
Time to Discuss Potentially Unpleasant Side Effects of COVID Shots? Scientists Say Yes.
From the likelihood of achy, flu-like side effects to the need for two doses, weeks apart, consumers need to know now what to expect when vaccines to prevent COVID-19 roll out.
By JoNel Aleccia and Liz Szabo -
Five Important Questions About Pfizer鈥檚 COVID-19 Vaccine
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
By Arthur Allen -
Search for a Snakebite Drug Might Lead to a COVID Treatment, Too
Human clinical trials are scheduled for a drug that could prevent some of the 100,000-plus deaths from snakebites worldwide each year. The same drug may also help people suffering from COVID-related acute respiratory distress.
By Jim Robbins -
VA Joins Pentagon in Recruiting Volunteers for COVID Vaccine Trials
The Department of Veterans Affairs hopes to enroll 8,000 people in advanced-stage trials of four leading vaccine candidates. The Defense Department earlier announced plans to enlist 3,000 volunteers in trials.
-
A $200 Debit Card Won鈥檛 Do Much for Seniors鈥 Drug Costs
President Donald Trump wants to send seniors $200 apiece. Beyond the legal and logistical problems, health care experts point out it does little to help someone with even typical prescription costs.
By Harris Meyer -
Letters to the Editor
Readers and Tweeters Shed Light on Vaccine Trials and Bias in Health Care
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
Scientists Warn Americans Are Expecting Too Much From a Vaccine
Some argue that vaccines capable of preventing any COVID-19 symptoms should qualify for widespread use, but others want much larger trials to prove the vaccines can reduce hospitalizations or deaths.
By Liz Szabo and JoNel Aleccia -
Florida Fails to Attract Bidders for Canada Drug Importation Program
No private firms bid on the $30 million contract to set up and operate the state鈥檚 plan to bring in cheaper drugs. The setback is likely to delay by at least several months Florida鈥檚 effort to become the first state to import drugs under new federal regulations.
-
Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not 鈥渇ighting鈥 for people with diabetes who struggle with the high cost of insulin.
-
As Trump Touts His 鈥楪reat鈥 COVID Drugs, the Pharma Cash Flows to Biden, Not Him
President Donald Trump has been heralding drugmakers as 鈥済reat companies.鈥 Yet in the final stretch of the presidential campaign, Trump is not feeling the love in pharma contributions. Former Vice President Joe Biden is, even though his proposed policies could dent the industry鈥檚 profitability.
By Jay Hancock -
5 Things to Know About a COVID Vaccine: It Won鈥檛 Be a 鈥楳agic Wand鈥
Approval of a vaccine will be an important step in defeating COVID-19. But it won鈥檛 immediately end the pandemic.
-
Not Pandemic-Proof: Insulin Copay Caps Fall Short, Fueling Underground Exchanges
Although sharing prescription medicines is illegal, many people with diabetes are turning to underground donation networks when they cannot afford their insulin. Caps on insulin copays enacted in Colorado and 11 other states were designed to help. But the gaps between insulin costs and many patients鈥 financial realities are only widening amid the economic crisis of the COVID pandemic.
-
Old Drug Turned 鈥楥ash Cow鈥 as Company Pumped Price to $40K a Vial, Emails Show
The CEO of Mallinckrodt Pharmaceuticals defended the price hikes of Acthar gel, an orphan drug that treats infantile spasms at a House Oversight Committee hearing on Thursday.
-
KHN鈥檚 鈥榃hat the Health?鈥: Election Preview: What鈥檚 Next for Health?
How will health issues affect voter choices? What will happen if President Donald Trump is reelected or the White House goes to Joe Biden? In this special election preview episode, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
-
New Laws Keep Pandemic-Weary California at Forefront of Health Policy Innovation
Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.
By Samantha Young and Angela Hart -
Sky-High Drug Prices Driven by Pharma Profits, House Dems Charge
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
-
Promises Kept? On Health Care, Trump’s Claims of 鈥楳onumental Steps’ Don鈥檛 Add Up
The president entered office seeking to overturn the Affordable Care Act, revamp Medicaid and drive down prescription drug prices, among other things. He鈥檚 hit some stone walls.
By Julie Rovner and Phil Galewitz -
Trump Approves Final Plan to Import Drugs From Canada 鈥榝or a Fraction of the Price鈥
The announcement clears the way for Florida and other states to implement a program bringing medications across the border to save money. The effort is strongly opposed by drugmakers and the Canadian government.